Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

Table 1 Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls

Genotypes	n (%)			P ^*	Alleles	n (frequency)			P°
Genotypes	NEO (n = 15)	MTS (n = 10)	CTR (n = 33)	P ^*	Alleles	NEO (2n = 30)	MTS (2n = 20)	CTR (2n = 66)	P°
FcγRIIIA 158V>F					FcγRIIIA 158V>F
V/V	4 (26.7)	3 (30.0)	6 (18.2)	0.741	V	13 (0.43)	8 (0.40)	26 (0.39)	0.934
V/F	5 (33.3)	2 (20.0)	14 (42.4)		F	17 (0.57)	12 (0.60)	40 (0.60)
F/F	6 (40.0)	5 (50.0)	13 (39.4)
HWE	P = 0.213	P = 0.065	P = 0.522
FcγRIIA 131H>R					FcγRIIA 131H>R
H/H	3 (20.0)	4 (40.0)	9 (27.3)	0.499	H	14 (0.47)	10 (0.50)	35 (0.53)	0.843
H/R	8 (53.3)	2 (20.0)	17 (51.5)		R	16 (0.53)	10 (0.50)	31 (0.47)
R/R	4 (26.7)	4 (40.0)	7 (21.2)
HWE	P = 0.782	P = 0.058	P = 0.845

Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)]
Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ² test (P* value) and the Fisher’s test (P° value), respectively. Statistical significance: P < 0.05
NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ² test (P < 0.05 indicates lack of HWE)

ISSN: 1479-5876